Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dengue 3 Human Infection Model (DENV-3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04298138
Recruitment Status : Not yet recruiting
First Posted : March 6, 2020
Last Update Posted : March 6, 2020
Sponsor:
Collaborators:
Walter Reed Army Institute of Research (WRAIR)
U.S. Army Medical Research and Development Command
Information provided by (Responsible Party):
State University of New York - Upstate Medical University

Brief Summary:
To evaluate the effectiveness of candidate dengue vaccine formulations, it is prudent to develop an appropriate challenge model. This study will examine the safety and effectiveness of the Dengue 3 Live Virus Human Challenge (DENV-3-LVHC) product and assess the ability of this virus strain to elicit an uncomplicated dengue-like illness.

Condition or disease Intervention/treatment Phase
Dengue Biological: Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC) Phase 1

Detailed Description:
Healthy subjects between 18 and 45 years old will be inoculated with Dengue 3 Live Virus Human Challenge (DENV-3-LVHC) in a dose ranging study. Subjects will be closely monitored for the first 28 days with continued follow up through 6 months. Clinical and laboratory parameters, viremia and antibody levels will be assessed. The goal is to determine the dose that produces uncomplicated dengue-like illness.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 27 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Nine subjects will be assigned to the low dose group. Twenty-one days post inoculation, data will be reviewed for safety and if performance parameters are met. If safety profile is acceptable but performance parameters have not been met, dose escalation to the medium dose will proceed in nine additional subjects. Twenty-one days post middle dose inoculation, data will be reviewed as above and a determination will be made to proceed to the high dose.
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Phase One, Open Label Assessment of a Dengue-3-Virus-Live Virus Human Challenge - (DENV-3-LVHC) Virus Strain
Estimated Study Start Date : March 8, 2020
Estimated Primary Completion Date : January 6, 2021
Estimated Study Completion Date : January 6, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dengue

Arm Intervention/treatment
Experimental: Low dose DENV-3-LVHC
Dengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single low dose (0.5 mL of 1.4 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
Biological: Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489 administered as a single injection.

Experimental: Medium dose DENV-3-LVHC
Dengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single medium dose (0.5 mL of 1.4 x 10^4 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
Biological: Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489 administered as a single injection.

Experimental: High dose DENV-3-LVHC
Dengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single high dose (0.5 mL of 1.4 x 10^5 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
Biological: Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489 administered as a single injection.




Primary Outcome Measures :
  1. Number of Abnormal Laboratory Measurements [ Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later ]
    Total number of all abnormal labs

  2. Intensity of Abnormal Laboratory Measurements [ Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later ]
    Graded according clinical laboratory normals and FDA toxicity scale

  3. Duration of Abnormal Laboratory Measurements [ Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later ]
    Number of days of abnormal lab

  4. Occurrence of Solicited Injection Site Symptoms [ Time Frame: 7 days post virus inoculation ]
    Number of solicited symptoms

  5. Intensity of Solicited Injection Site Symptoms [ Time Frame: 7 days post virus inoculation ]
    Graded according to FDA toxicity scale

  6. Duration of Solicited Injection Site Symptoms [ Time Frame: 7 days post virus inoculation ]
    Number of days per symptom

  7. Occurrence of Unsolicited Injection Site Symptoms [ Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later ]
    Number of unsolicited site symptoms

  8. Intensity of Unsolicited Injection Site Symptoms [ Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later ]
    Graded according to FDA toxicity scale

  9. Duration of Unsolicited Injection Site Symptoms [ Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later ]
    Number of days per symptom

  10. Occurrence of Solicited Systemic Symptoms [ Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later ]
    Number of solicited systemic symptoms

  11. Intensity of Solicited Systemic Symptoms [ Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later ]
    Graded according to FDA toxicity scale

  12. Duration of Solicited Systemic Symptoms [ Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later ]
    Number of days per symptom

  13. Occurence of Unsolicited Systemic Symptoms [ Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later ]
    Number of unsolicited systemic symptoms

  14. Intensity of Unsolicited Systemic Symptoms [ Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later ]
    Graded according to FDA toxicity scale

  15. Duration of Unsolicited Systemic Symptoms [ Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later ]
    Number of days per symptom

  16. Number of Serious Adverse Events [ Time Frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later ]
    Total number

  17. Number of Serious Adverse Events [ Time Frame: 6 months post virus inoculation ]
    Total number


Secondary Outcome Measures :
  1. Incubation period before onset of fever [ Time Frame: Up to 28 days post virus inoculation ]
    Number of days prior to fever

  2. Viremia by Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) [ Time Frame: Up to 28 days post virus inoculation ]
    Levels of viremia

  3. Occurence of fever [ Time Frame: Up to 28 days post virus inoculation ]
    Defined as greater than or equal to 38°C (100.4°F) measured at least 2 times in 24 hours but not lasting more than 72 hours

  4. Occurrence of Headache [ Time Frame: Up to 28 days post virus inoculation ]
    Number of headaches

  5. Grade of Headache [ Time Frame: Up to 28 days post virus inoculation ]
    Graded according to FDA toxicity scale

  6. Occurrence of Myalgia [ Time Frame: Up to 28 days post virus inoculation ]
    Number of reported myalgias

  7. Grade of Myalgia [ Time Frame: Up to 28 days post virus inoculation ]
    Graded according to FDA toxicity scale

  8. Occurrence of Rash [ Time Frame: Up to 28 days post virus inoculation ]
    Number of rashes

  9. Grade of Rash [ Time Frame: Up to 28 days post virus inoculation ]
    Graded according to FDA toxicity scale

  10. Occurrence of Abnormal Liver Function Test [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)] [ Time Frame: Up to 28 days post virus inoculation ]
    Number of abnormal liver function tests

  11. Grade of Abnormal Liver Function Test [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)] [ Time Frame: Up to 28 days post virus inoculation ]
    Graded according clinical laboratory normals and FDA toxicity scale

  12. Occurrence of Leukopenia [ Time Frame: Up to 28 days post virus inoculation ]
    Number of occurrences

  13. Grade of Leukopenia [ Time Frame: Up to 28 days post virus inoculation ]
    Graded according clinical laboratory normals and FDA toxicity scale

  14. Occurrence of Thrombocytopenia [ Time Frame: Up to 28 days post virus inoculation ]
    Number of occurrences

  15. Grade of Thrombocytopenia [ Time Frame: Up to 28 days post virus inoculation ]
    Graded according clinical laboratory normals and FDA toxicity scale



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Age 18-45 at the time of consent
  2. Ability and willingness to sign informed consent
  3. Passing score on comprehension test of at least 75%, with up to 3 attempts
  4. Available for the study period
  5. Willing to use contraception for the duration of the study
  6. Provide consent for release of medical history records from primary care physician, college or university, urgent care or emergency room visit

Exclusion Criteria:

  1. Female: pregnant or lactating
  2. Heavy menstrual bleeding within the last 6 months- menstrual periods lasting longer than 6 days, or requiring 5 or more pads or tampons per day.
  3. Female subjects using an intrauterine device (IUD) or Mirena®
  4. Female subjects with fibroids or uterine polyps, endometriosis, adenomyosis, and uterine scarring (e.g., after D&C)
  5. Blood tests confirming infection with human immunodeficiency virus- 1 (HIV-1), hepatitis C, hepatitis B (assessed by HbsAg) virus, or positive antibodies to the flaviviruses (FV) dengue, West Nile, Yellow Fever, Japanese encephalitis, or Zika.
  6. Active Diabetes or active peptic ulcer disease (PUD)
  7. Chronic obstructive pulmonary disease (COPD) or coronary artery disease (CAD)
  8. Known or suspected congenital or acquired immunodeficiency; or receipt of immunomodulation therapy such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  9. Current, or a history of, auto-immune disease
  10. History of Guillain-Barré syndrome (GBS)
  11. Any history of FV infection or FV vaccination; or planned FV vaccination, outside the study protocol, during the study period
  12. Diagnosis with Bipolar Disorder or Schizophrenia, hospitalization in the past year for a mental health disorder, or any other psychiatric condition, which in the opinion of the investigator prevents the subject from participating in the study.
  13. Planned travel during the study period (180 days) which would interfere with the ability to complete all study visits
  14. Recent (in the past 4 weeks) travel to any dengue endemic area. These potential subjects may be eligible for enrollment a minimum of 4 weeks later
  15. Any laboratory abnormalities prior to inoculation for the tests specified in Table 18 and Table 19 of the protocol, that are considered by the investigator to be clinically significant except those listed in exclusion criteria 16
  16. Subjects with the following grade 2 or greater lab abnormalities: Creatinine; Liver Function Tests - ALT, AST; Hemoglobin (females and males); White Blood Cell (WBC) decrease; Platelets decreased; Prothrombin Time (PT); Partial Thromboplastin Time (PTT); Fibrinogen decrease
  17. Significant screening physical examination abnormalities at the discretion of the investigator
  18. Women who intend to become pregnant or men who intend to father a child during the study period (approximately 180 days)
  19. Hives, shortness of breath, swelling of the lips or throat, or hospitalization related to a previous vaccination or an allergy to specific medications/animals for which antigens may be in the virus preparations to include: shellfish allergy, fetal bovine serum, L-glutamine, neomycin and streptomycin
  20. Planning to donate blood in the 1 year following inoculation with dengue
  21. Recent blood donation within prior 56 days of inoculation
  22. Receipt of blood products or antibodies within 56 days of inoculation or during the study period
  23. Participation (active or follow-up phase) or planned participation in another vaccine, drug, medical device, or medical procedure clinical trial in the 4 weeks prior to this trial, during the trial, or 6 months following inoculation in this clinical trial
  24. Recent or scheduled receipt of any vaccine 4 weeks prior to or after virus inoculation
  25. Beliefs that bar the administration of blood products or transfusions
  26. Positive urine screen for cocaine, amphetamines, or opiates
  27. Currently taking Methadone or Suboxone
  28. Currently taking anti-coagulant medication, aspirin or non-steroidal anti-inflammatory drugs (NSAIDs)
  29. Chronic migraine headaches, defined as more than 15 headache days per month over a 3-month period of which more than 8 are migraines, in the absence of medication over use
  30. Chronic medical condition that, in the opinion of the investigator, impacts subject safety.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04298138


Contacts
Layout table for location contacts
Contact: Keely Terrillion 3154649869 trials@upstate.edu

Locations
Layout table for location information
United States, New York
State University of New York, Upstate Medical University (SUNY-UMU)
Syracuse, New York, United States, 13210
Sponsors and Collaborators
State University of New York - Upstate Medical University
Walter Reed Army Institute of Research (WRAIR)
U.S. Army Medical Research and Development Command
Investigators
Layout table for investigator information
Principal Investigator: Timothy P Endy, MD, MPH State University of New York, Upstate Medical University (SUNY-UMU)
Layout table for additonal information
Responsible Party: State University of New York - Upstate Medical University
ClinicalTrials.gov Identifier: NCT04298138    
Other Study ID Numbers: 2019-01-UMU
First Posted: March 6, 2020    Key Record Dates
Last Update Posted: March 6, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by State University of New York - Upstate Medical University:
Dengue
Flavivirus Infections
Virus Diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Dengue
Arbovirus Infections
Virus Diseases
Flavivirus Infections
Flaviviridae Infections
RNA Virus Infections
Hemorrhagic Fevers, Viral